Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cervical Cancer Recurrent × RC48 antibody × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 2 Ovarian Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Muscle Invasive Bladder Cancer 1 Head and Neck Neoplasms 1 HER2-positive Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Endometrial Neoplasms 1 Cervical Cancer Recurrent 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

tislelizumab 1 RC48 antibody 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06063018 2023-10-02

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Peking Union Medical College Hospital

Phase 2 Recruiting

Cervical Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡